Department of Laboratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P.R. China.
J Cell Biochem. 2020 Jan;121(1):596-608. doi: 10.1002/jcb.29305. Epub 2019 Aug 12.
Cervical cancer is the third leading cause of female death in the world. Serum microRNAs (miRNAs) are currently considered to be valuable as noninvasive cancer biomarkers, but their role in the prognosis of cervical cancer has not been elucidated. We aimed to find serum miRNAs that can be used as prognostic factors for cervical cancer. A traumatic pathological biopsy is the only reliable method for determining the severity of cervical cancer currently. Thus, noninvasive diagnostic markers are needed. The serological expression of candidate miRNAs were measured in 90 participants, including 60 patients with cervical cancer and 50 patients with cervical intraepithelial neoplasia. Two patients with cervical cancer were excluded from the study because of lack of data. miRNAs were evaluated by quantitative reverse transcription polymerase chain reaction. miR-143/-4636 appeared specific for cervical cancer compared with cervical intraepithelial neoplasia (P < .001). The classification performance of validated miRNAs for cervical cancer [Area under the receiver operating characteristic curve (AUC) = 0.942] was better than that reached by squamous cell carcinoma antigen (SCC-Ag; AUC = 0.727). Poor-differentiation group has lower miR-143/-4636 levels in serum (P < .05). miR-4636 level was correlated gross tumor volume and the depth of invasion (P < .0001). In our study, we found a combination of miR-143 and miR-4636 that is independently and strongly associated with cervical cancer prognosis and can be used as a clinically prognostic factor.
宫颈癌是全球女性死亡的第三大主要原因。血清 microRNAs（miRNAs）目前被认为是有价值的非侵入性癌症生物标志物，但它们在宫颈癌预后中的作用尚未阐明。我们旨在寻找可作为宫颈癌预后因素的血清 miRNAs。目前，确定宫颈癌严重程度的唯一可靠方法是创伤性病理活检。因此，需要非侵入性诊断标志物。在 90 名参与者中测量了候选 miRNAs 的血清表达，其中包括 60 名宫颈癌患者和 50 名宫颈上皮内瘤变患者。由于缺乏数据，两名宫颈癌患者被排除在研究之外。通过定量逆转录聚合酶链反应评估 miRNAs。miR-143/-4636 与宫颈上皮内瘤变相比，对宫颈癌具有特异性（P<.001）。验证的 miRNAs 对宫颈癌的分类性能[受试者工作特征曲线下面积（AUC）=0.942]优于鳞状细胞癌抗原（SCC-Ag；AUC=0.727）。低分化组血清中 miR-143/-4636 水平较低（P<.05）。miR-4636 水平与大体肿瘤体积和浸润深度相关（P<.0001）。在我们的研究中，我们发现了 miR-143 和 miR-4636 的组合，它们独立且与宫颈癌预后强烈相关，可以用作临床预后因素。
